IWC International Workshop Criteria LDH Lactate dehydrogenase MAA Marketing Authorisation Application MedDRA Medical Dictionary for Regulatory Activities MINE Mesna, ifosfamide, etoposide MSKCC Memorial Sloan Kettering Cancer NCCN National Comprehensive Cancer Network NCI National Cancer Institute NE Not evaluable NHL Non-Hodgkin’s lymphoma NOS Not otherwise specified NR Not reported ORR Overall response rate OS Overall survival PD Progressive disease PFS Progression-free survival PMitCEBO Prednisone, mitoxantrone, cyclophosphamide, etoposide, bleomycin, Oncovin (vincristine) PR Partial response PS Performance status PTCL Peripheral T-cell lymphoma R-DHAP Rituximab, dexamethasone, high-dose ara-C, and cisplatin RICE Rituximab-ifosfamide, carboplatin, etoposide SD Stable disease SD90 Stable disease for 90 days or longer SOC SPD System organ class Sum of product diameter
IWC International Workshop Criteria LDH Lactate dehydrogenase MAA Marketing Authorisation Application MedDRA Medical Dictionary for Regulatory Activities MINE Mesna, ifosfamide, etoposide MSKCC Memorial Sloan Kettering Cancer NCCN National Comprehensive Cancer Network NCI National Cancer Institute NE Not evaluable NHL Non-Hodgkin’s lymphoma NOS Not otherwise specified NR Not reported ORR Overall response rate OS Overall survival PD Progressive disease PFS Progression-free survival PMitCEBO Prednisone, mitoxantrone, cyclophosphamide, etoposide, bleomycin, Oncovin (vincristine) PR Partial response PS Performance status PTCL Peripheral T-cell lymphoma R-DHAP Rituximab, dexamethasone, high-dose ara-C, and cisplatin RICE Rituximab-ifosfamide, carboplatin, etoposide SD Stable disease SD90 Stable disease for 90 days or longer SOC SPD System organ class Sum of product diameter
auspar-romidepsin-131120-cer.docx